Novo-Nordisk is a healthcare company. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. The diabetes and obesity care segment covers insulin, GLP-1 and related delivery systems, oral antidiabetic products, obesity and other diseases. The biopharm segment covers the therapy areas of haemophilia, growth disorders and hormone replacement therapy. Co.'s products include NovoLog®/ NovoRapid®, NovoLog Mix®/ NovoMix®, Levemir®, Victoza®, Tresiba®, Ryzodeg®, Xultophy®, Fiasp®, Ozempic®, Saxenda®, Rybelsus® , NovoSeven®, NovoEight®, Rebinyn®/ Refixia®, Norditropin®, Esperoct® and devices. The NVO stock yearly return is shown above.
The yearly return on the NVO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NVO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|